LEO Pharma’s emission reduction targets validated by the Science Based Targets initiative
The validation confirms that LEO Pharma’s climate targets to reduce green-house gas emissions are in line with the Paris Agreement.
LEO Pharma is proud to announce the validation of its Scope 1 & 2 and Scope 3 targets by the Science Based Targets initiative (SBTi).
Emission reduction targets are considered science-based if they are in line with what the latest climate science says is necessary to meet the goals of the Paris Agreement – to limit global warming to well-below 2°C above pre-industrial levels and pursue efforts to limit warming to 1.5°C.
“Climate change is impacting all of us – as individuals and as a business. Setting science-based targets provides LEO Pharma with a defined pathway for reducing our greenhouse gas emissions to keep global warming to 1.5°C and is part of our commitment to building a responsible business.” said Rhonda Duffy, Executive Vice President, Global Product Supply, LEO Pharma. “We realize that we do not have all the answers to how we will reach these targets, so we have a great task ahead of us in engaging with suppliers and business partners and looking for solutions that can help LEO Pharma prepare for the transition towards a low-carbon economy.”
“We congratulate LEO Pharma on setting science-based targets consistent with limiting warming to 1.5°C, the most ambitious goal of the Paris Agreement," said Alberto Carrillo Pineda, Managing Director, Science Based Targets at CDP, one of the Science Based Targets initiative partners. "By setting ambitious science-based targets grounded in climate science, LEO Pharma is taking action to prevent the most damaging effects of climate change."
LEO Pharma’s climate targets involve:
- Own operations (Scope 1 and 2): LEO Pharma commits to reducing our carbon emissions from own operations by more than 50% from 2019 to 2030.
- Value chain (Scope 3): LEO Pharma commits to ensuring that 75% of our suppliers by emissions have set science-based targets by 2026. Suppliers by emission cover purchased goods and services, capital goods and upstream transportation.
To ensure consistency with the most recent climate science, we will review, and if necessary, recalculate our science-based target, at a minimum every 5 years or if significant changes occur that would compromise the relevance and consistency of the existing target.
LEO Pharma’s sustainability approach is designed to respond to the societal challenges facing our business - now and in the future. Health is LEO Pharma’s core business. Climate change is a societal challenge that has an impact on health, as it undermines social factors for good health such as equality and access to healthcare. LEO Pharma is committed to operating responsibly and minimizing the negative impact of our operations on the environment.
- ENDS -
 The Science Based Targets initiative (SBTi) is a collaboration between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi defines and promotes best practices in science-based target setting and independently assesses companies’ targets. Currently, almost 2000 companies have joined SBTi.
+45 3140 6180
About LEO Pharma
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
Japan Ministry of Health, Labor and Welfare Approves Manufacturing and Marketing of Adtralza® (tralokinumab) in Japan for Adults with Atopic Dermatitis23.12.2022 06:22:48 CET | Press release
BALLERUP, Denmark, 23, December 2022 – LEO Pharma A/S, a global leader in medical dermatology, announced today that the Japan Ministry of Health, Labor and Welfare (MHLW) has granted approval for the manufacturing and marketing of Adtralza® (tralokinumab) subcutaneous injection (S.C.) for adults with atopic dermatitis, which has inadequately responded to conventional therapies.
LEO Pharma announces positive phase 3 topline results from DELTA 1 trial with delgocitinib cream in adults with moderate to severe chronic hand eczema (CHE)6.12.2022 08:00:00 CET | Press release
• The first phase 3 clinical trial (DELTA 1) with delgocitinib cream in adults with moderate to severe chronic hand eczema (CHE) met primary and all key secondary endpoints • DELTA 1 trial results show that delgocitinib cream provided early symptom-relief in a hard-to-treat disease • The majority of adverse events observed were non-serious, mild or moderate in severity, and not considered treatment related
LEO PHARMA LAUNCHES AD DAYS AROUND THE WORLD CAMPAIGN TO RAISE AWARENESS OF THE IMPACT OF ATOPIC DERMATITIS ACROSS CULTURES3.10.2022 07:00:00 CEST | Press release
• In partnership with Global patient advocate Ashley Ann Lora, AD Days Around the World explores the impact of atopic dermatitis (AD) on the lives of individuals around the world living with this chronic and debilitating skin disease • The campaign features the emotional journey of four patient advocates from France, Italy, Germany and Spain and showcases the impact that AD has on people, regardless of culture or geography
LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis29.9.2022 07:00:00 CEST | Press release
LEO Pharma and DKSH have entered into an agreement to bring high-quality therapeutic products for dermatology and thrombosis to patients across Asia. This agreement both supports LEO Pharma’s strategy of building a simpler and more competitive organization and DKSH Business Unit Healthcare’s strategic focus of strengthening its regional footprint.
LEO Pharma receives positive CHMP opinion of Adtralza® (tralokinumab) for the treatment of adolescents with moderate-to-severe atopic dermatitis19.9.2022 07:30:00 CEST | Press release
• Positive CHMP opinion recommends extending use of Adtralza® (tralokinumab) to adolescents (12-17 years old) in the European Union (EU) • Recommendation supported by data from the Phase 3 ECZTRA 6 trial
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom